IMMUNO-ONCOLOGICAL TREATMENT OF NON-SMALL-CELL LUNG CANCER IN ADVANCED STAGE WITH NIVOLUMAB

Abstract

In recent years, significant scientific progress has been made in the therapy of non-small cell lung cancer (NSCLC),which has made possible a better knowledge of this pathology and above all the realization of new personalized therapies. The main therapeutic revolution in advanced NSCLC is immunooncology, a new therapeutic strategy that aims to awaken the immune system to fight cancer cells. Our work helped us evaluate the therapeutic efficacy of monotherapy with Nivolumab in the treatment of patients with advanced stage IIIB/IV non-smallcell lung cancer beyond the second line. We can conclude that in the treatment of non-small-cell lung cancer, the use of Nivolumab improves the prognosis and quality of life of the patients, without causing serious side effects compared to other treatments. We hope that in the future the combination of predictive biomarker research combined with the improvement of Immunoncology protocols will led to ever greater overall survival data.